NeOnc Technologies Holdings, Inc. Joins Russell Microcap® Index

Rhea-AI Summary

NeOnc Technologies Holdings (NASDAQ: NTHI), a clinical-stage biopharmaceutical company developing CNS cancer treatments, has been added to the Russell Microcap® Index following its 2025 annual reconstitution. This inclusion positions NTHI among select companies with market caps between $30 million and $3 billion, representing less than 3% of the U.S. equity market.

The company is currently advancing two Phase II clinical trials with its proprietary NEO100™ and NEO212™ therapeutics, both operating under FDA Fast-Track and IND status. NeOnc's drug development platform focuses on overcoming blood-brain barrier challenges, with patent protections extending to 2038. The company is also pursuing strategic expansion in the MENA region through a proposed partnership with Quazar in the GCC.

Positive

• Inclusion in Russell Microcap® Index, providing exposure to $10.6 trillion in benchmarked assets
• Two drug candidates (NEO100™ and NEO212™) in Phase II trials with FDA Fast-Track status
• Patent protection extending to 2038 for proprietary technology
• Strategic expansion potential through proposed Quazar partnership in GCC region

Negative

• Early clinical-stage company with no commercialized products yet
• Uncertainty regarding final terms of Quazar partnership
• Potential risks associated with clinical trial outcomes

News Market Reaction

-0.92%

1 alert

-0.92% News Effect

On the day this news was published, NTHI declined 0.92%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CALABASSAS, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, has joined the Russell Microcap® Index following the conclusion of the 2025 Russell indexes annual reconstitution.

The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks ranking them by total market capitalization. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

“Joining the Russell Microcap® Index is a powerful validation of NeOnc’s momentum and our unwavering commitment to shareholder value and patient impact,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, Inc. “This index represents microcap companies with an average market cap of about $640 million, covering stocks between roughly $30 million and $3 billion across fewer than 3% of the U.S. equity market. Over the past year, we’ve been intensely focused on advancing our Phase II clinical trials in CNS cancers and strategically expanding into the MENA region through our proposed Quazar partnership in the GCC. Our ultimate goal remains the same: to generate meaningful shareholder returns while making a real difference for patients and families battling brain cancer.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell's US indexes serve as the benchmark for about $10.6 trillion in assets as of the close of June 2024. Russell indexes are part of FTSE Russell, the global index provider.

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.

Important Cautions Regarding Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.

Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.

The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.

We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.

“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Company Contact:


info@neonc.com

Investor Contact:


James Carbonara

Hayden IR

646)-755-7412

James@haydenir.com 

FAQ

What does NeOnc Technologies' (NTHI) inclusion in the Russell Microcap Index mean for investors?

The inclusion provides NTHI with increased visibility and exposure to institutional investors, as Russell indexes serve as benchmarks for about $10.6 trillion in assets. This membership remains in place for one year and includes automatic inclusion in growth and value style indexes.

What are the main products in NeOnc Technologies' (NTHI) clinical pipeline?

NeOnc has two main products in development: NEO100™ and NEO212™, both currently in Phase II clinical trials. These therapeutics have FDA Fast-Track and IND status, targeting malignant gliomas and other CNS cancers.

How long does NeOnc Technologies' (NTHI) patent protection extend?

NeOnc's patent portfolio, licensed from the University of Southern California, extends to 2038, covering NEO100, NEO212, and other products for oncological and neurological conditions.

What is NeOnc Technologies' (NTHI) expansion strategy in the MENA region?

NeOnc is pursuing strategic expansion through a proposed partnership with Quazar in the GCC (Gulf Cooperation Council) region, though the agreement terms are still being finalized.

What is the focus of NeOnc Technologies' (NTHI) drug development platform?

NeOnc's NEO™ platform focuses on developing central nervous system therapeutics specifically designed to overcome blood-brain barrier challenges in treating CNS cancers and disorders.